TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15196153

Group type: EXPERIMENTAL
Intervention: RA/beta‐CD complex hydrogel formulation (0.025%)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RA/beta‐CD complex in moisturizing base (0.025%)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hydrogel placebo base
Number of subjects: 66

Group type: COMPARATOR
Intervention: Moisturizer placebo base
Number of subjects: 66

Group type: COMPARATOR
Intervention: Commercial RA product (0.05%)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RA/beta‐CD complex in moisturizing base
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RA/beta‐CD complex hydrogel formulation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RA/beta‐CD preparations
Number of subjects: 66
Study: 11772826

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (12 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bupivacaine (12 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (4-12 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bupivacaine (4-12 mg)
Number of subjects: 18
Study: 10586386

Group type: EXPERIMENTAL
Intervention: Oral midazolam (2 mg) with ketoconazole (200 mg) given 2 hours prior to probes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral midazolam (2 mg) with ketoconazole (200 mg) given simultaneously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Erythromycin breath test (3 microCi)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral midazolam (2 mg)
Number of subjects: 12
Study: 8933995

Group type: EXPERIMENTAL
Intervention: Alniditan 1.2 mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Alniditan 1.4 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 1860148

Group type: EXPERIMENTAL
Intervention: 750 mg mefloquine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1250 mg mefloquine
Number of subjects: 20
Study: 6349649

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium (300 mg/day)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 27036157

Group type: EXPERIMENTAL
Intervention: Change-related SOC (self-efficacy)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Ending in change-related SOC
Number of subjects: 225
Study: 29733110

Group type: EXPERIMENTAL
Intervention: CO2 laser at 5% density
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CO2 laser at 15% density
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 5% density
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 15% density
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unanesthetized reference
Number of subjects: 15
Study: 27609756

Group type: EXPERIMENTAL
Intervention: Immediate combination antiretroviral therapy (cART)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Deferred cART
Number of subjects: 53

Group type: COMPARATOR
Intervention: Immediate cART vs Deferred cART
Number of subjects: 53
Study: 24439714

Group type: EXPERIMENTAL
Intervention: FLUSH test (agitated saline solution flush)
Number of subjects: 51
Study: 23375921

Group type: EXPERIMENTAL
Intervention: Tooth-anchored treatment group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bone-anchored treatment group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 20646352

Group type: EXPERIMENTAL
Intervention: Propolis and zinc suspension
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control (elimination of environmental risk factors only)
Number of subjects: 122
Study: 18766414

Group type: EXPERIMENTAL
Intervention: Monopolar floating ball (MFB)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Bipolar forceps (BF)
Number of subjects: 76
Study: 16023821

Group type: EXPERIMENTAL
Intervention: GP desktop resource (GDR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concern about the doctor‐patient relationship
Number of subjects: 0
Study: 12954743

Group type: EXPERIMENTAL
Intervention: Buprenorphine (16 mg) and Naloxone (4 mg)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Buprenorphine alone (16 mg)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study: 10829350

Group type: EXPERIMENTAL
Intervention: Rivastigmine (Exelon‐Novartis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Donepezil (Aricept‐Eisai; Pfizer)
Number of subjects: 0
Study: 8874905

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 272

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 272
Study: 1577043

Group type: EXPERIMENTAL
Intervention: Immediate release paracetamol 500 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Immediate release paracetamol 1000 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sustained release paracetamol 2000 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3001149

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 6 g/d for 6 d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DCHA) 6 g/d for 6 d
Number of subjects: 0
Study: 31394993

Group type: EXPERIMENTAL
Intervention: Clazosentan 5 mg/h
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Clazosentan 15 mg/h
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1718
Study: 28846541

Group type: EXPERIMENTAL
Intervention: 6.5 Fr SheathLess hydrophilic‐coated guide catheter (SH‐GC)
Number of subjects: 600

Group type: COMPARATOR
Intervention: 6.0 Fr Glidesheath Slender (GSS)
Number of subjects: 600
Study: 27304603

Group type: EXPERIMENTAL
Intervention: POD FineVision IOL
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: FineVision/MicroF IOL
Number of subjects: 21
Study: 25491243

Group type: EXPERIMENTAL
Intervention: Indexed stories
Number of subjects: 103

Group type: COMPARATOR
Intervention: Randomly selected stories
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Text or animated conversational agent
Number of subjects: 103
Study: 22772859

Group type: EXPERIMENTAL
Intervention: PEEP 5 cm H2O
Number of subjects: 52

Group type: COMPARATOR
Intervention: ZEEP (PEEP 0 H2O)
Number of subjects: 52
Study: 20428872

Group type: EXPERIMENTAL
Intervention: Hospira filgrastim (10 microg/kg, i.v.)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Amgen filgrastim (10 microg/kg, i.v.)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hospira filgrastim (10 microg/kg, s.c.)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Amgen filgrastim (10 microg/kg, s.c.)
Number of subjects: 48
Study: 18672110

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: All treatments (EE, IBU, PL)
Number of subjects: 107
Study: 15962651

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily for 30 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 30 weeks
Number of subjects: 42
Study: 12885681

Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment
Number of subjects: 3564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3564
Study: 10190398

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study: 8754377

Group type: EXPERIMENTAL
Intervention: Fraxiparin, antibiotic, Metronidazole, and prostaglandins
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 143
Study: 8261257

Group type: EXPERIMENTAL
Intervention: Serum cholesterol reduction
Number of subjects: 0
Study: 2956865

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg enoximone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg enoximone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg/kg enoximone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg enoximone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 mg/kg enoximone
Number of subjects: 60
Study: 31403552

Group type: EXPERIMENTAL
Intervention: Cold Pulsatile Machine Perfusion (MP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Static Cold Storage (CS)
Number of subjects: 51
Study: 29562983

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for at least 6 months
Number of subjects: 974

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 974
Study: 27334562

Group type: EXPERIMENTAL
Intervention: VAS response scale version
Number of subjects: 446

Group type: COMPARATOR
Intervention: Likert-type response scale version
Number of subjects: 446
Study: 27164919

Group type: EXPERIMENTAL
Intervention: High-polyphenol diet (6 portions of fruit and vegetables including 1 portion of berries/day and 50g of dark chocolate)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low-polyphenol diet (continued for 8 weeks)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High-polyphenol diet
Number of subjects: 92
Study: 23649508

Group type: EXPERIMENTAL
Intervention: UPPP + Repose
Number of subjects: 78

Group type: COMPARATOR
Intervention: UPPP alone
Number of subjects: 78
Study: 21859733

Group type: EXPERIMENTAL
Intervention: Second-generation tyrosine kinase inhibitors (nilotinib or dasatinib)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Interferon-α therapy (control group)
Number of subjects: 350
Study: 19758824

Group type: EXPERIMENTAL
Intervention: Soy protein diet (35% soy protein, 35% animal protein, 30% other vegetable proteins)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Animal protein diet (70% animal and 30% vegetable proteins)
Number of subjects: 14
Study: 17074639

Group type: EXPERIMENTAL
Intervention: AZD7009 (3‐hour intravenous infusion)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: AZD7009
Number of subjects: 122
Study: 15658649

Group type: EXPERIMENTAL
Intervention: Quchi needling (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Captopril (Control Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Taichong needling (Group A)
Number of subjects: 60
Study: 11708589

Group type: EXPERIMENTAL
Intervention: Computer program intervention (10 half-hour sessions over 2 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 9950305

Group type: EXPERIMENTAL
Intervention: Isoprinosine (50 mg/kg per day for 6 weeks followed by 50 mg/kg per day twice weekly for 6 weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 7522017

Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2783023

Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Number of subjects: 252

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 252
Study: 1090174

Group type: EXPERIMENTAL
Intervention: Deladumone OB
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 31977668

Group type: EXPERIMENTAL
Intervention: Tuberosity-Based Plate (TBP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard Proximal Humeral Locking Plate (PHLP)
Number of subjects: 10
Study: 31719010

Group type: EXPERIMENTAL
Intervention: Triclosan-coated suture
Number of subjects: 508

Group type: COMPARATOR
Intervention: Conventional non-antibiotic suture
Number of subjects: 508
Study: 28802565

Group type: EXPERIMENTAL
Intervention: EUS-guided pancreatic cyst lavage with normal saline (alcohol-free group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: EUS-guided pancreatic cyst lavage with 80% ethanol (control group)
Number of subjects: 39
Study: 25335249

Group type: EXPERIMENTAL
Intervention: Warming‐promotion acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Regular acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Care group (psychological treatment)
Number of subjects: 90
Study: 24330450

Group type: EXPERIMENTAL
Intervention: Standard surgical technique
Number of subjects: 150

Group type: COMPARATOR
Intervention: Alternative technique with coverage of the pancreatic remnant by the falciform ligament
Number of subjects: 150
Study: 20855064

Group type: EXPERIMENTAL
Intervention: MMC (magnetic maneuverable capsule)
Number of subjects: 10

Group type: COMPARATOR
Intervention: ESO2 (conventional capsule)
Number of subjects: 10
Study: 25159907

Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 136
Study: 17221169

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (20 mg) b.i.d for 3 months plus scaling and root planing (SRP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo capsules b.i.d for 3 months plus scaling and root planing (SRP)
Number of subjects: 65
Study: 12926129

Group type: EXPERIMENTAL
Intervention: CT + RT (three courses of chemotherapy followed by radiotherapy)
Number of subjects: 61

Group type: COMPARATOR
Intervention: RT (radiotherapy alone)
Number of subjects: 61
Study: 10830459

Group type: EXPERIMENTAL
Intervention: Self-paced system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard bottle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Test bottle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vacuum-free bottle
Number of subjects: 0
Study: 2349253

Group type: EXPERIMENTAL
Intervention: Cocaine-base 10 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cocaine-base 20 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cocaine-base 40 mg
Number of subjects: 5
Study: 106428

Group type: EXPERIMENTAL
Intervention: Ciclazindol 50 mg orally
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tandamine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ciclazindol
Number of subjects: 15
Study: 30506893

Group type: EXPERIMENTAL
Intervention: Right ventricular fractional area change
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Right ventricular indexed end-diastolic volume
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Right ventricular indexed end-systolic volume
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: RV ejection fraction increase
Number of subjects: 283
Study: 29084796

Group type: EXPERIMENTAL
Intervention: Financial incentives conditional on attending scheduled pregnancy follow‐up consultations
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 2000
Study: 25366969

Group type: EXPERIMENTAL
Intervention: Higher dose budesonide/formoterol (HDBF) 640/18 μg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (BFMRT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (terbutaline 1 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (lower dose budesonide/formoterol)
Number of subjects: 120
Study: 24398815

Group type: EXPERIMENTAL
Intervention: Computerised treatment group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 23025249

Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation (R&R) program
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation (R&R) program (completers)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 84
Study: 18945254

Group type: EXPERIMENTAL
Intervention: ROSE-010 300 microg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: ROSE-010 100 microg
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: ROSE-010 (both doses)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: ROSE-010
Number of subjects: 166
Study: 17763150

Group type: EXPERIMENTAL
Intervention: Aspirin treatment (81, 162 and 325 mg/day for 4 weeks each)
Number of subjects: 110
Study: 16172177

Group type: COMPARATOR
Intervention: Placebo-controlled intervention, average trial size of 32 subjects at 5 dose levels.
Number of subjects: 3323

Group type: COMPARATOR
Intervention: Crossover designs (more frequent in early publications) and parallel single-dose designs.
Number of subjects: 3323
Study: 12473551

Group type: EXPERIMENTAL
Intervention: S-nitrosoglutathione (GSNO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9872244

Group type: EXPERIMENTAL
Intervention: Neonatal screening
Number of subjects: 53781
Study: 7699439

Group type: EXPERIMENTAL
Intervention: Indium-111-pentetreotide
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional imaging methods
Number of subjects: 47
Study: 2642633

Group type: EXPERIMENTAL
Intervention: Diltiazem (n = 13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 24
Study: 7383476

Group type: EXPERIMENTAL
Intervention: 1% econazole vaginal cream, used once daily at bedtime for 7 days
Number of subjects: 178

Group type: COMPARATOR
Intervention: 100‐mg clotrimazole vaginal tablets, used once daily at bedtime for 7 days
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 178
Study: 30859941

Group type: EXPERIMENTAL
Intervention: 20mg amphetamine sulfate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30mg amphetamine sulfate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 40mg amphetamine sulfate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29061602

Group type: EXPERIMENTAL
Intervention: Attention training via an online probe detection task with images of faces displaying neutral and disgusted expressions
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 31
Study: 26018054

Group type: EXPERIMENTAL
Intervention: Preincisional trocar wound infiltration with bupivacaine (group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preincisional trocar wound infiltration and intraperitoneal instillation of bupivacaine (group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 0
Study: 25085960

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Percutaneous coronary revascularization with drug-eluting stents (DES-PCI)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800

Group type: COMPARATOR
Intervention: DES-PCI
Number of subjects: 1800
Study: 22520932

Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide (V/HCTZ) 160/12.5 mg
Number of subjects: 301

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 301

Group type: COMPARATOR
Intervention: Valsartan (V) 160 mg
Number of subjects: 301
Study: 20170329

Group type: EXPERIMENTAL
Intervention: Feedback on adherence during review consultations
Number of subjects: 26

Group type: COMPARATOR
Intervention: Undisclosed adherence to parents and treating physician
Number of subjects: 26
Study: 18063452

Group type: EXPERIMENTAL
Intervention: Standard volume of local anaesthetic containing 2% lidocaine and 1/80,000 adrenaline
Number of subjects: 45

Group type: COMPARATOR
Intervention: Double the standard volume with 1% lidocaine and 1/160,000 adrenaline
Number of subjects: 45
Study: 16110841

Group type: EXPERIMENTAL
Intervention: Acid perfusion in healthy volunteers
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Acid exposure in healthy epithelium
Number of subjects: 3

Group type: COMPARATOR
Intervention: Acid exposure in GERD patients
Number of subjects: 3
Study: 11818921

Group type: EXPERIMENTAL
Intervention: Reusable straight‐shaft spiked forceps
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Reusable angled‐shaft spiked forceps
Number of subjects: 75

Group type: COMPARATOR
Intervention: Disposable lateral cup forceps
Number of subjects: 75
Study: 10424505

Group type: EXPERIMENTAL
Intervention: HFA cromolyn sodium (2 mg, two inhalations, qid for 12 weeks)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: CFC cromolyn sodium (2 mg, two inhalations, qid for 12 weeks)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 2324880

Group type: EXPERIMENTAL
Intervention: Electronic scale (SMART; Olympic Medical)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mechanical scale (Toledo)
Number of subjects: 50
Study: 6114524

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 23

Group type: COMPARATOR
Intervention: DSCG
Number of subjects: 23
Study: 30547261

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Trunk stabilization exercises
Number of subjects: 45

Group type: COMPARATOR
Intervention: Routine cardiac rehabilitation programme (Control)
Number of subjects: 45
Study: 28236769

Group type: COMPARATOR
Intervention: ECRF group
Number of subjects: 2686

Group type: COMPARATOR
Intervention: RIEC group
Number of subjects: 2686
Study: 26408562

Group type: EXPERIMENTAL
Intervention: Surgical management (drainage)
Number of subjects: 3444

Group type: COMPARATOR
Intervention: Nonsurgical management (medical)
Number of subjects: 3444

Group type: EXPERIMENTAL
Intervention: Overall complication rate
Number of subjects: 3444
Study: 23916919

Group type: EXPERIMENTAL
Intervention: Counselor-delivered intervention
Number of subjects: 489

Group type: COMPARATOR
Intervention: Web-based intervention
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Both interventions (counselor-delivered and web-based)
Number of subjects: 489
Study: 21478216

Group type: EXPERIMENTAL
Intervention: Mannitol (400 mg b.i.d.)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 324
Study: 19583518

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for ASB
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Treatment only for symptomatic infections
Number of subjects: 105

Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 105
Study: 17889086

Group type: EXPERIMENTAL
Intervention: 20 mg of iron daily in the second half of pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 0
Study: 15173273

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid (via a 15-minute infusion every 3 weeks for 15 months)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 11294919

Group type: EXPERIMENTAL
Intervention: Gabapentin 3,600 mg daily for 9 months
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204